DUSP16 (dual specificity phosphatase 16), also known as MKP7, is a phosphatase that negatively regulates mitogen-activated protein kinase (MAPK) signaling. Functionally, DUSP16 dephosphorylates multiple MAPK family members, with particular specificity for c-Jun N-terminal kinase (JNK) and p38 MAPK 1. DUSP16 localizes to the cytoplasm, nucleoplasm, and nucleus, where it binds to MAP kinase substrates 2. Mechanistically, DUSP16 protein stability is controlled by ubiquitin-mediated degradation 3, and can be targeted by F-box proteins like FBXL18 for proteasomal destruction 4. Its expression is transcriptionally regulated by ELK1 in pathological conditions 5. DUSP16 suppresses JNK and p38 phosphorylation, thereby inhibiting downstream apoptotic pathways and reducing BAX mitochondrial accumulation 6. DISEASE RELEVANCE: DUSP16 dysfunction is implicated in multiple cancers. High DUSP16 expression correlates with chemotherapy resistance in nasopharyngeal, colorectal, gastric, and breast cancers by suppressing JNK/p38-mediated apoptosis 6. In bladder cancer, KLF16-mediated DUSP16 mRNA destabilization reduces DUSP16 levels, activating ERK1/2 signaling and promoting tumor progression 2. In endometrial carcinoma, FBXL18-induced DUSP16 degradation activates JNK signaling to enhance proliferation and invasion 4. DUSP16 ablation induces cellular senescence through p53/Rb activation, suggesting tumor-suppressive potential 7. In Alzheimer's disease, elevated DUSP16 impairs neural progenitor differentiation 5. CLINICAL SIGNIFICANCE: DUSP16 serves as a prognostic biomarker for chemotherapy sensitivity and outcome. Targeting DUSP16 upregulation represents a therapeutic strategy for overcoming drug resistance and promoting neurogenesis in neurodegenerative diseases.